Henlius And Outlook Move Forward With Ophthalmic Bevacizumab
Positive Results For Henlius’ Essex-Partnered HLX04-O, As Outlook Re-Submits In US
Henlius has reported progress in its development of a bevacizumab product for treating ophthalmic diseases, with its Essex-partnered HLX04-O candidate meeting its primary endpoint in a Phase III trial. Meanwhile, Outlook Therapeutics has taken another shot at getting its own ophthalmic bevacizumab approved in the US after resubmitting its filing.
